Inotuzumab ozogamicin
Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).